The tumour-agnostic + informed blood test will aid in residual disease monitoring

Datar Cancer Genetics (DCG) has launched Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid organ cancers. Target-MRD is a blood test based on tumour-agnostic next-generation sequencing (NGS) and customised, tumour-informed droplet digital PCR (dd-PCR) assay.

Target-MRD offers personalised, ultra-sensitive detection and monitoring of residual disease at the molecular level, if any, to assist oncologists in intervening early, well before the disease gets out of hand. Target-MRD combines tumour-agnostic (to detect tumour evolution) and tumour-informed (specific to a patient's cancer) biomarkers thus offering a comprehensive and ultra-high sensitivity solution for more effective disease management.

Dr Timothy Crook, Consultant Medical Oncologist, Cromwell Hospital, London, said, "Monitoring the slightest recurrence of cancer in patients after treatment is critical to enable timely interventions before the disease gets out of hand. The dual approach of Datar's MRD is a significant step forward in non-invasively detecting the earliest signs of residual disease. It has the potential to change how we manage cancer patients." 

"This novel MRD detection approach, combining tumor-informed and tumor-agnostic strategies, represents a significant advancement in oncology diagnostics. This innovative methodology enhances our ability to deliver truly personalised care to cancer patients. Its sensitivity and precision offer clinicians invaluable tools for tailoring treatments, improving recurrence detection, and optimising long-term patient outcomes. This is a transformative step toward truly personalised cancer care," said Dr Ashok Kumar Vaid, Chairman, Medical Oncology, Medanta Hospital, Gurugram.

"Target-MRD reflects DCG's commitment to safe, reliable and accurate technologies. It is the next generation test that has the potential not only to detect recurrence earlier but to adapt itself to each patient's requirements and helps to personalise cancer management decisions," said Dr Darshana Patil, Senior Director, Global Strategy and Medical Affairs at DCG.